cemka > Publications > Pharmaco-Economics

Sort publications on year

  • Pharmaco-Economics

    Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care : an analysis conducted on the UK General Practitioner Research Database

    LAFUMA A, LAURENDEAU C, BERDEAUX G

    J Med Econ ; 11(3):485-497

  • Pharmaco-Economics

    Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by the United Kingdom General Practitioner Research Database

    DENIS P, LAFUMA A, BERDEAUX G

    Clin Ophtalmol ; 2(2):321-329

  • Pharmaco-Economics

    Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients : A French adaptation of CARDS

    LAFUMA A, COLIN X, SOLESSE A

    Arch Cardiovasc Dis ; 2008;101(5):327-332

  • Pharmaco-Economics

    Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France

    STANDAERT B, PAREZ N, TEHARD B, COLIN X, DETOURNAY B

    Appl Health Econ Health Policy ; 6(4):199-216

  • Pharmaco-Economics

    Aspects épidémiologiques et économiques de l’insulinothérapie en Fance métropolitaine

    DETOURNAY B

    Med Mal Metab ; (2):149-152

  • Pharmaco-Economics

    Evaluation économique du trastuzumab en traitement adjuvant du cancer du sein précoce surexprimant HER2

    FAGNANI F, COLIN X, ARVEUX P, COUDERT B, MISSET JL

    Bulletin du Cancer ; 94(7):711-720

  • Pharmaco-Economics

    Coût de l’obésité en France

    EMERY C, DINET J, LAFUMA A, SERMET C, KHOSHNOOD B, FAGNANI F

    Presse Med ; 832-840

  • Pharmaco-Economics

    Invasive cervical cancer treatment costs in France

    ARVEUX P, BENARD S, BOUEE S, LAFUMA A, MARTIN L, CRAVELLO L, REMY V, BREUGELMANS JG

    Bull Cancer ; 94(2):219-224

  • Pharmaco-Economics

    Coût de la prise en charge des frottis anormaux et des néoplasies intraépithéliales du col de l’utérus en France

    BERGERON C, COHET C, BOUEE S, LORANS C, REMY V

    BEH ; (1):4-6

  • Pharmaco-Economics

    Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma : analysis conducted on the United Kingdom General Practitioner Research Database

    LAFUMA A, BERDEAUX G

    Curr Med Res Opin ; 23(12):3009-3016

  • Pharmaco-Economics

    Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting

    DOUILLARD JY, TILLEUL P,YCHOU M, DUFOUR P, PERROCHEAU G, SEITZ JF, MAES P, LAFUMA A, HUSSEINI F

    Oncology ; 72:248-254

  • Pharmaco-Economics

    A model of the public health impact of improved treatment persistence in post-meopausal osteoroposis in France

    COTTE FE, CORTET B, LAFUMA A, AVOUAC B, HASNAOUI AE, FADELLONE P, POUCHAIN D, ROUX C, GAUDIN AF

    Joint Bone Spine ; 31

  • Pharmaco-Economics

    Nonmedical economic consequences attribuables to visual impairment nation-wide approach in France

    LAFUMA A, BREZIN A, FAGNANI F, MIMAUD V, MESBAH M, BERDEAUX G

    Eur J Health Econom ; 7(3):158-164

  • Pharmaco-Economics

    Evaluation of non-medical costs associated with visual impairment in four European countries – France, Italy, Germany and the UK

    LAFUMA A, BREZIN A, LAPATRIELLO S, HIEKE K, HUTCHINSON J, MIMAUD V, BERDEAUX G

    Pharmacoeconomics ; 24(2):193-205

  • Pharmaco-Economics

    Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries

    BOUEE S, LAFUMA A, FAGNANI F, MEUNIER PJ, REGINSTER JY

    Rheumatol Int ; 26(12):1063-72